Abstracts tagged "B cells"

Abstract Number: 563 • 2013 ACR/ARHP Annual Meeting
Hold The Rituximab: Neuropsychiatric Disease In Murine Lupus Is Not B-Cell Dependent
Jing Wen¹, Ariel Stock¹, Haowei Wang², Mark Shlomchik², Maria Gulinello¹ and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric disease is one of the earliest clinical manifestations in systemic lupus erythematosus (SLE). However, the mechanisms leading to neuropsychiatric SLE (NPSLE) are not…
Abstract Number: 2905 • 2013 ACR/ARHP Annual Meeting
Demethylation of ITGAL (CD11a) regulatory sequences in CD4+T lymphocytes of Systemic Sclerosis
Yaoyao Wang¹, Ye Shu², Qing Wang¹, Ming Zhao¹, Gongping Liang¹, Qianjin Lu¹ and Rong Xiao¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Department of Dermatology, Hunan Children's Hospital, Changsha, China

Background/Purpose: Systemic sclerosis (SSc) is an autoimmune connective tissue disease epitomized numerous cellular and humoral immunological abnormalities. The immune system undoubtedly plays a pivotal…
Abstract Number: 1604 • 2013 ACR/ARHP Annual Meeting
Effects Of Chronic Treatment With Blisibimod, An Inhibitor Of B Cell Activating Factor, On Renal and Inflammation Biomarkers In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod on renal and inflammation biomarkers in patients with SLE during the phase 2b clinical trial PEARL-SC (NCT01162681)…
Abstract Number: 568 • 2013 ACR/ARHP Annual Meeting
Pneumococcal Polysaccharide Vaccination Regulates T and B Lymphocyte Cytokine Responses and Decreases Kidney Stat1 Levels In MRL/Lpr Mice In Vivo
Victor Gazivoda¹, Shikha Mehta², Luhan Wang³, Julia Ash⁴, Kirk E. Sperber³ and Ioannis Tassiulas³, ¹Medicine, New York Medical College, Valhalla, NY, ²New York Medical College, Valhalla, NY, ³Medicine-Rheumatology, New York Medical College, Valhalla, NY, ⁴Rheumatology, New York Medical College, Valhalla, NY
Background/Purpose: Zwitterionic polysaccharides can activate CD4+ T cells after processing and presentation by antigen-presenting cells. The 23-valent capsular polysaccharide pneumococcal vaccine, PneumoVax, protects against invasive…
Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Alexis Boneparth^1,2, Ramalingam Bethunaickan³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Feinstein Institute for medical Research, Manhasset, NY, ³Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
Abstract Number: 1402 • 2013 ACR/ARHP Annual Meeting
Regulatory B10 Cells Are Decreased In Patients With Rheumatoid Arthritis and Inversely Correlated With Disease Activity
Claire I. Daien^1,2, Sarah Gailhac³, Thibault Mura⁴, Bernard Combe⁵, Michael Hahne¹ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Igmm UMR3555, CNRS, Montpellier, France, ⁴CIC, Hopital Gui De Chauliac, Montpellier, France, ⁵Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Regulatory IL-10 producing B cells (B10) have been shown to prevent and cure collagen-induced arthritis in mice. In human, very little is known about…
Abstract Number: 41 • 2013 ACR/ARHP Annual Meeting
Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity
Peter Schafer¹, Emily Rychak², Derek Mendy³, Stacey Parton¹, Lori Capone⁴, Antonia Lopez-Girona², Dorota Cedzik⁵, Jolanta Kosek⁵, Ling-Hua Zhang⁵ and Rajesh Chopra⁵, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Molecular & Medical Science, Celgene Signal Research, San Diego, CA, ³Celgene Signal Research, San Diego, CA, ⁴Celgene Corporation, Summit, NJ, ⁵Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex including CUL4A, DDB1, and ROC-1. CC-220 is a novel immunomodulatory compound currently in…
Abstract Number: 2798 • 2013 ACR/ARHP Annual Meeting
Bone Marrow In Systemic Lupus Erythematosus Patients Contain a Highly Elevated Proportion Of Somatically Mutated, Activated Naive Cells Comprised Of Substantial Clonal Expansions
Jennifer Hom¹, Christopher Tipton², Christopher Fucile³, Bridget Neary¹, Chungwen Wei⁴, F. Eun-Hyung Lee¹, Alex Rosenberg³ and Inaki Sanz², ¹Emory University, Atlanta, GA, ²Medicine/Rheumatology, Emory University, Atlanta, GA, ³University of Rochester, Rochester, NY, ⁴Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease where autoreactive antibodies are produced as a result of abnormal B cell activation and broken self-tolerance. This…
Abstract Number: 1383 • 2013 ACR/ARHP Annual Meeting
Validation Of Popliteal Lymph Node Phenotype and Bin Expansion As Biomarkers Of Rheumatoid Arthritis Knee Flare
Homaira Rahimi¹, Ronald Wood², Igor Kuzin³, Wakenda Tyler⁴, Gregory Dieudonne⁵, Stephen Kates⁶, Christopher T. Ritchlin³ and Edward M. Schwarz⁷, ¹Pediatrics, University of Rochester, Rochester, NY, ²Department of Urology, University of Rochester Medical Center, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Orthopedics, University of Rochester, Rochester, NY, ⁵Radiology, University of Rochester, Rochester, NY, ⁶Orthopedic Surgery, University of Rochester Medical Center, Rochester, NY, ⁷Center for Musculoskeletal Research, University of Rochester, Rochester, NY
Background/Purpose: Factors precipitating joint flare in rheumatoid arthritis (RA) patients are poorly understood. Contrast enhanced (CE) MRI studies in murine models have identified popliteal lymph…
Abstract Number: 42 • 2013 ACR/ARHP Annual Meeting
Inhibition Of B Cell Differentiation To The Plasmablast and Plasma Cell Lineage By CC-220, a Potent Modulator Of The Cereblon E3 Ubiquitin Ligase Complex
Peter Schafer¹, Lori Capone², Lei Wu¹ and Rajesh Chopra³, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Celgene Corporation, Summit, NJ, ³Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose: CC-220 is an immunomodulatory compound which binds to the CUL4 family E3 ubiquitin ligase complex protein cereblon (CRBN) with high affinity and modulates the…
Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting
Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Elena Becerra¹, Inmaculada de la Torre², Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College London, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
Abstract Number: 1752 • 2012 ACR/ARHP Annual Meeting
Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing
Hamid Mattoo¹, Arezou Khosroshahi², Vinay Mahajan³, Mollie Carruthers², John Stone³ and Shiv Pillai⁴, ¹Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Boston, MA, ³Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Oncology, Massachusetts General Hospital, Boston, MA
Depletion of CD4-effector memory T cells and clonally expanded IgG4 memory B cells may explain the therapeutic efficacy of rituximab in IgG4-related disease: Studies using…
Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Thomas J. A. Lehman¹, Emily Baird², Anusha Ramanathan³, Risa Alperin³, Emma J. MacDermott³, Alexa B. Adams³, Laura V. Barinstein³ and Lakshmi N. Moorthy⁴, ¹Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, ²Hospital for Special Surgery, NY, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…
Abstract Number: 1759 • 2012 ACR/ARHP Annual Meeting
Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Abby Jones Weldon¹, Sheri Hsu², Seyed K. Nazeri³, Saru Sachdeva², Jennifer Gonzalez⁴, Andrea D. Parra⁵, Abigail Benitez¹, Keith K. Colburn⁶, Ioana Moldovan⁷ and Kimberly J. Payne⁸, ¹Microbiology and Molecular Genetics, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ³Rheumatology, Loma Lida University Medical Center, Loma Lida, CA, ⁴Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁵Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁶Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA
Background/Purpose: Autoimmune disease affects more than 23 million Americans. Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are chronic, systemic B-cell mediated autoimmune diseases. During…
Abstract Number: 1754 • 2012 ACR/ARHP Annual Meeting
Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
Marieke E. Doorenspleet¹, Paul L. Klarenbeek¹, Maartje J. Boumans¹, Rogier M. Thurlings², Rebecca E. Esveldt¹, Barbera D. van Schaik³, Antoine H. van Kampen³, Danielle M. Gerlag⁴, Frank Baas⁵, Paul-Peter Tak¹, Robert M. Plenge⁶ and Niek de Vries¹, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Bioinformatics, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Genome Analysis, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoreactive B lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].